ALBIREO PHARMA WKN: A2DF99 ISIN: US01345P1066 Kürzel: BDQM Forum: Aktien Thema: Hauptdiskussion

Wie geht es denn weiter mit diesem erfolgsabhängigen Teil (10 Dollar je Aktie). Ist es realistisch, dass das ausgezahlt wird?

Leider ist das Übernahmeangebot nicht der Pipeline entsprechend

https://www.sharedeals.de/albireo-pharma-sd-rakete-mit-88-dank-uebernahmeangebot/

von 0 auf 100 - so schnell

👀

Und wie läuft das dann ab? Muss ich verkaufen und wenn ja, wann ist das sinnvoll?

Ipsen übernimmt Albireo für 952 Millionen

@abeni Guten Morgen 😘

🧐

Albireo Pharma präsentiert Daten aus den Phase-3-Studien PEDFIC 1 und PEDFIC 2

Reports Positive Topline Data from Phase 3 Trial of Bylvay (odevixibat) in Alagille Syndrome. Highly statistically significant improvement in pruritus primary endpoint (p=0.002) Significant reductions in key secondary endpoint of serum bile acid levels (p=0.001)

🤩

Albireo gibt Vereinbarung zur Monetarisierung von Lizenzgebühren in Höhe von 115 Millionen US-Dollar mit Sagard bekannt

👀

Sehr schön das es so langsam voran geht

Albireo Pharma, Inc. (NASDAQ:ALBO) Expected to Post Quarterly Sales of $12.30 Million Posted on Wednesday, February 2nd, 2022 by MarketBeat Brokerages forecast that Albireo Pharma, Inc. (NASDAQ:ALBO) will post $12.30 million in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Albireo Pharma's earnings, with the highest sales estimate coming in at $23.12 million and the lowest estimate coming in at $5.01 million. Albireo Pharma reported sales of $2.72 million in the same quarter last year, which would suggest a positive year over year growth rate of 352.2%. The company is scheduled to report its next earnings results on Thursday, February 24th. According to Zacks, analysts expect that Albireo Pharma will report full-year sales of $18.34 million for the current financial year, with estimates ranging from $12.00 million to $31.18 million. For the next fiscal year, analysts forecast that the business will report sales of $53.22 million, with estimates ranging from $42.48 million to $58.67 million. Zacks Investment Research's sales calculations are an average based on a survey of research firms that cover Albireo Pharma. Albireo Pharma (NASDAQ:ALBO) last issued its quarterly earnings data on Thursday, November 4th. The biopharmaceutical company reported $2.90 earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $3.28. The business had revenue of $3.66 million during the quarter, compared to the consensus estimate of $22.33 million. Albireo Pharma had a negative net margin of 444.28% and a negative return on equity of 82.99%. During the same quarter in the prior year, the firm posted ($1.96) earnings per share.